Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of SP2086 in Subjects With Liver Impairment
NCT06035406Phase 1Not yet recruiting
- Sponsor
- Hengrui
- Start
- Sep 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of retagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 1 more. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
retagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06035406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06035406.